This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.
‘The blue inhaler is a killer,’ says expert

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.
Debbie Rigby takes a look at the latest in research news Clinical impact of antipsychotic and benzodiazepine reduction Data from the Reducing Use of Sedatives (RedUSe) project involved 150 Australian aged care homes demonstrates that antipsychotic and benzodiazepine dose reduction was not associated with deterioration in neuropsychiatric symptoms, quality of…
Proposal for combination asthma inhalers to be downscheduled to Pharmacist Only with Appendix M controls for ‘as needed’ use A request has been made for the TGA to downschedule budesonide-formoterol fixed dose combination (FDC) inhalers to Schedule 3, for use as an anti-inflammatory reliever in people aged 12 years and…
New indication means budesonide/formoterol can be prescribed as needed (PRN) for patients with mild asthma, without daily maintenance treatment Symbicort Turbuhaler 200/6 and Symbicort Rapihaler 100/3 can now be prescribed to Australian adult and adolescent asthma patients (12 years and over) of any asthma severity, following registration by the TGA to…
All content on AJP.com.au is restricted to registered users only.
To continue enjoying access to all the news, views, information and education you’ve come to trust, please login & stay in.
And if you don’t already have a login – register now!
Notifications